Pharmacokinetics
As with all potent bisphosphonates, the fraction of the drug that reaches the circulatory system intact (systemic bioavailability) after oral dosing is low, averaging only 0.6–0.7% in women and in men under fasting conditions. Intake together with meals and beverages other than water further reduces the bioavailability. The absorbed drug rapidly partitions, with approximately 50% binding to the exposed bone surface; the remainder is excreted unchanged by the kidneys. Unlike with most drugs, the strong negative charge on the two phosphonate moieties limits oral bioavailability, and, in turn, the exposure to tissues other than bone is very low. After absorption in the bone, alendronate has an estimated terminal elimination half-life of 10 years. References
External links
"Alendronic acid". Drug Information Portal. U.S. National Library of Medicine. "Alendronate sodium". Drug Information Portal. U.S. National Library of Medicine.
See also
The Myelin Project
The Stennis Foundation

References
External links

OMIM entries on Alexander disease
Infantile-onset Alexander disease in a child with long-term follow-up by serial magnetic resonance imaging: a case report
Alexander Disease: New Insights From Genetics